Version 1
: Received: 29 February 2024 / Approved: 29 February 2024 / Online: 29 February 2024 (12:55:04 CET)
How to cite:
Niazi, S.K.; Magoola, M.; Mariam, Z. Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease. Preprints2024, 2024021734. https://doi.org/10.20944/preprints202402.1734.v1
Niazi, S.K.; Magoola, M.; Mariam, Z. Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease. Preprints 2024, 2024021734. https://doi.org/10.20944/preprints202402.1734.v1
Niazi, S.K.; Magoola, M.; Mariam, Z. Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease. Preprints2024, 2024021734. https://doi.org/10.20944/preprints202402.1734.v1
APA Style
Niazi, S.K., Magoola, M., & Mariam, Z. (2024). Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease. Preprints. https://doi.org/10.20944/preprints202402.1734.v1
Chicago/Turabian Style
Niazi, S.K., Matthias Magoola and Zamara Mariam. 2024 "Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease" Preprints. https://doi.org/10.20944/preprints202402.1734.v1
Abstract
Alzheimer's disease (AD) remains a significant challenge in the field of neurodegenerative disor-ders, even nearly a century after its discovery, due to the elusive nature of its causes. The develop-ment of drugs that target multiple aspects of the disease has emerged as a promising strategy to address the complexities of AD and related conditions. The immune system's role, particularly in AD, has gained considerable interest, with nanobodies representing a new frontier in biomedical research. Advances in targeting antibodies against amyloid-β (Aβ) and using messenger RNA for genetic translation have revolutionized the production of antibodies and drug development, open-ing new possibilities for treatment. Despite these advancements, conventional treatments for AD, such as Cognex, Exelon, Razadyne, and Aricept, often have limited long-term effectiveness, under-scoring the need for innovative solutions. This necessity has led to the incorporating of advanced technologies like artificial intelligence and machine learning into the drug discovery process for neurodegenerative diseases. These technologies help identify therapeutic targets and optimize lead compounds, offering a more effective approach to addressing the challenges of AD and similar conditions.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
